Saturday, July 17, 2010

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients


By Bob DeMarco
Alzheimer's Reading Room

This phase 3 clinical trial is being sponsored by Wyeth. Wyeth is now part of Pfizer (PFE).

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.


Criteria

Inclusion:
  • Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
  • Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
  • Caregiver will participate and be able to attend clinic visits with patient.

Exclusion:
  • Significant neurological disease other than AD, or a major psychiatric disorder
  • Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
  • Woman of childbearing potential

There are 253 study locations participating.

Go here

for a list of locations.


Subscribe to the Alzheimer's Reading Room
Enter Your Email Address

More About the Alzheimer's Reading Room




The Alzheimer's Action Plan
 
300 Tips for Making Life Easier


Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,610 articles with more than 8,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, the Alzheimer's Reading Room